During the past decade several display methods and other library screening techniques
have been developed for isolating monoclonal antibodies (mAbs) from large collections of …

Viruses have evolved to enter cells from all three domains of life—Bacteria, Archaea and
Eukaryotes. Of more than 3,600 known viruses, hundreds can infect human cells and most of …

The third variable region (V3) of the HIV-1 gp120 envelope glycoprotein is immunodominant
and contains features essential for coreceptor binding. We determined the structure of V3 in …

A protective vaccine against HIV-1 will likely require the elicitation of a broadly neutralizing
antibody (bNAb) response. Although the development of an immunogen that elicits such …

ABSTRACT 2G12 is a broadly neutralizing human monoclonal antibody against human
immunodeficiency virus type-1 (HIV-1) that has previously been shown to bind to a …

Broadly neutralizing monoclonal antibodies (MAbs) are potentially important tools in human
immunodeficiency virus type 1 (HIV-1) vaccine design. A few rare MAbs have been …

Licensed vaccines against viral diseases generate antibodies that neutralize the infecting
virus and protect against infection or disease. Similarly, an effective vaccine against HIV-1 …

Several human monoclonal antibodies (hmAbs) including b12, 2G12, and 2F5 exhibit
relatively potent and broad HIV-1-neutralizing activity. However, their elicitation in vivo by …

The study of the evolution and specificities of neutralizing antibodies during the course of
human immunodeficiency virus type 1 (HIV-1) infection may be important in the discovery of …

Anti-human immunodeficiency virus type 1 (HIV-1) antibodies whose binding to gp120 is
enhanced by CD4 binding (CD4i antibodies) are generally considered nonneutralizing for …